In 2011, researchers in Israel published the first study evaluating the effect of cannabis on patients with Crohn’s disease. All patients stated that consuming cannabis had a positive effect, ameliorating disease activity and reducing the need for other conventional medications. The researchers hypothesized that the observed beneficial effect in this study may be due to the anti-inflammatory properties of cannabis, but additional effects of cannabinoids may also play a role. (more…)
A 2013 study Published in the journal Pharmacology involved 21 patients with Crohn’s disease unresponsive to standard IBD treatment. The study was able to demonstrate that an 8-week treatment with tetrahydrocannabinol (THC)-rich cannabis caused a decrease in the Crohn’s disease activity index in 90% of patients without producing significant side effects. (more…)
From research out of Israel, and published in the October, 2013 issue of Clinical Gastroenterology and Hepatology, comes this controlled trial showing that a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn’s disease, compared with placebo, without side effects. (more…)
If you are a patient with inflammatory bowel disease, IBD, using cannabis to mitigate the symptoms of Crohn’s disease or ulcerative colitis, you are invited to participate in this study. Any patient who describes him/herself as having IBD can fill out the IBD questionnaire, personalized with a unique code number, (Study number) and your email address.
If you would like for your data to be entered into the official study database, we ask that you provide adequate pathological evidence or physician verification of the IBD diagnosis in a release of medical information to the principle investigator, (more…)